Preclinical News and Research

RSS

Promising new target for brain tumor therapy

A drug that targets the body's immune cells may be effective in treating malignant brain tumors, according to a new study led by researchers from Duke's Preston Robert Tisch Brain Tumor Center.

9 May 2007

LigoCyte Pharmaceuticals presents data showing that immunization with their influenza H1N1-VLP formulation resulted in 100% protection from H1N1 and H3N2

LigoCyte Pharmaceuticals has presented preclinical data showing that immunization with their influenza virus-like particles (VLPs) induced heterosubtypic protection in a virus challenge study.

4 May 2007

Mesoblast receives FDA clearance for heart attack stem cell trial

Australia's adult stem cell company, Mesoblast Limited has announced that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) of its US-based sister company, Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or 'off-the-shelf', adult stem cells for patients with heart attacks.

4 May 2007

Revolutionary treatment for blindness

The first clinical trial to test a revolutionary treatment for blindness in children has been announced by researchers at UCL (University College London).

2 May 2007

Exposure to secondhand tobacco smoke increases the risk of developing dementia

Based on preliminary results, the study authors found that elderly people with high lifetime exposure to secondhand smoke were approximately 30 percent more likely to develop dementia than those with no lifetime secondhand smoke exposure.April 28, May 5, 2007.

2 May 2007

Cancer Research Technology licenses therapeutic antibodies to Peptech

Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announces it has licensed rights to a panel of cancer therapeutic antibodies to Peptech Limited.

2 May 2007

Avicena files composition of matter patent application for treatment of Huntington's disease

Avicena Group has announced day that it has filed a composition of matter patent application with the United States Patent and Trademark Office (USPTO) to cover potential treatments for Huntington's disease, a fatal neurodegenerative disease.

1 May 2007

Link found between bile duct obstruction and bile duct cancer

When bile duct cancer cells were placed in the liver of animals with bile duct obstruction, they grew more rapidly than identical cells placed in animals without bile duct obstruction.

30 Apr 2007

Sangamo BioSciences starts phase 2 trial of therapy diabetic neuropathy

Sangamo BioSciences has announced that the company has initiated a repeat-dosing, multi-center Phase 2 clinical trial of SB-509 in subjects with moderate to severe diabetic peripheral sensory motor neuropathy (DN).

27 Apr 2007

Avicena files composition of matter patent application for treatment of Parkinson's disease

Avicena Group, Inc. has announced that it has filed a composition of matter patent application with the United States Patent and Trademark Office to cover potential treatments for Parkinson's disease, a progressive neurodegenerative disease.

27 Apr 2007

Gold nanoparticles for early detection of cancer

By attaching gold nanoparticles - like tiny balls or rods- to cancer cells, earlier detection will be possible.

24 Apr 2007

M. D. Anderson wins $8.3-million to research environmental causes of major diseases

An $8.3-million federal grant to The University of Texas M. D. Anderson Cancer Center Science Park - Research Division addresses the complex interplay between such varied factors as genetics, diet, and environmental exposure to toxins that cause cancer, asthma, diabetes, cardiovascular and other diseases.

21 Apr 2007

Schering-Plough plans phase III trials for novel selective antiplatelet therapy

Schering-Plough Corporation has announced plans to initiate two global Phase III large-scale clinical outcomes trials for its novel selective oral antiplatelet therapy, the thrombin receptor antagonist (TRA) SCH 530348.

20 Apr 2007

Access Pharmaceuticals and Somanta Pharmaceuticals sign merger agreement

Access Pharmaceuticals and Somanta Pharmaceuticals have announced that they have signed a definitive merger agreement by which Access will acquire Somanta.

20 Apr 2007

Protalix BioTherapeutics receives FDA approval to initiate a phase III trial of prGCD

Protalix BioTherapeutics, Inc. has announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in the United States of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher Disease, a lysosomal storage disorder in humans.

19 Apr 2007

Lexicon-Genentech reveals potential therapeutic targets

Lexicon Genetics Incorporated has announced that data was presented highlighting potential therapeutic targets related to its collaboration with Genentech, Inc. at the Society for Biomolecular Sciences 13th Annual Conference & Exhibition in Montreal, Canada.

19 Apr 2007